Neu Base Therapeutics
Pharmaceuticals, 350 Technology Dr Ste 421, Pittsburgh, Pennsylvania, 15219, United States, 11-50 Employees
Phone Number: 14*********
Who is NEUBASE THERAPEUTICS
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, for which there are no approved therapies, as well as more common genetic disorders, including ...
Read More
-
Headquarters: 350 Technology Dr Ste 421, Pittsburgh, Pennsylvania, 15219, United States
-
Date Founded: 2018
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from NEUBASE THERAPEUTICS
NeuBase Therapeutics Org Chart and Mapping
Email
Phone
Ranajoy Sarkar
Senior Vice President and Head, Corporate Strategy & Business Development
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding NeuBase Therapeutics
Answer: NeuBase Therapeutics's headquarters are located at 350 Technology Dr Ste 421, Pittsburgh, Pennsylvania, 15219, United States
Answer: NeuBase Therapeutics's phone number is 14*********
Answer: NeuBase Therapeutics's official website is https://neubasetherapeutics.com
Answer: NeuBase Therapeutics's revenue is $1 Million to $5 Million
Answer: NeuBase Therapeutics's SIC: 2834
Answer: NeuBase Therapeutics's NAICS: 325412
Answer: NeuBase Therapeutics has 11-50 employees
Answer: NeuBase Therapeutics is in Pharmaceuticals
Answer: NeuBase Therapeutics contact info: Phone number: 14********* Website: https://neubasetherapeutics.com
Answer: NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase’s pipeline includes therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington's disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.”
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month